Boston scientific initiates avant guard clinical trial to evaluate farapulse™ pulsed field ablation system as first-line treatment for persistent atrial fibrillation

Marlborough, mass. , dec. 28, 2023 /prnewswire/ -- boston scientific corporation (nyse: bsx) has initiated the avant guard clinical trial to evaluate the safety and effectiveness of the farapulse™ pulsed field ablation (pfa) system* as a first-line treatment for persistent atrial fibrillation (af), the only trial to study the use of pfa as frontline therapy in patients with this form of af.
BSX Ratings Summary
BSX Quant Ranking